CZ293919B6 - Prostředek schopný reagovat na magnetické pole - Google Patents

Prostředek schopný reagovat na magnetické pole Download PDF

Info

Publication number: CZ293919B6
Authority: CZ; Czechia
Prior art keywords: particles; iron; ceramic; composition; biologically active
Prior art date: 1999-10-18

Application number

CZ20021357A

Other languages

Czech (cs)

English (en)

Other versions

CZ20021357A3 (cs

Inventor

Rudgeáscottáraymond

Kurtzáterriálynn

Tapolskyágillesáhugues

Liáyuhua

Original Assignee

Ferxáincorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-18

Filing date

2000-10-13

Publication date

2004-08-18

2000-10-13 Application filed by Ferxáincorporated filed Critical Ferxáincorporated

2002-11-13 Publication of CZ20021357A3 publication Critical patent/CZ20021357A3/cs

2004-08-18 Publication of CZ293919B6 publication Critical patent/CZ293919B6/cs

Links

239000000203 mixture Substances 0.000 title claims abstract description 56
239000002245 particle Substances 0.000 claims abstract description 139
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 100
239000000919 ceramic Substances 0.000 claims abstract description 54
229910052742 iron Inorganic materials 0.000 claims abstract description 47
238000001727 in vivo Methods 0.000 claims abstract description 12
239000013543 active substance Substances 0.000 claims description 37
229910010293 ceramic material Inorganic materials 0.000 claims description 37
230000005291 magnetic effect Effects 0.000 claims description 36
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
238000000034 method Methods 0.000 claims description 27
229910052588 hydroxylapatite Inorganic materials 0.000 claims description 26
239000000546 pharmaceutical excipient Substances 0.000 claims description 15
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 14
239000011148 porous material Substances 0.000 claims description 14
239000000377 silicon dioxide Substances 0.000 claims description 11
239000007864 aqueous solution Substances 0.000 claims description 9
108090000623 proteins and genes Proteins 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 7
230000005855 radiation Effects 0.000 claims description 6
239000002246 antineoplastic agent Substances 0.000 claims description 4
238000009472 formulation Methods 0.000 claims description 4
239000000741 silica gel Substances 0.000 claims description 4
229910002027 silica gel Inorganic materials 0.000 claims description 4
YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
229920000249 biocompatible polymer Polymers 0.000 claims description 2
238000010894 electron beam technology Methods 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
229930195725 Mannitol Natural products 0.000 claims 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
239000000994 contrast dye Substances 0.000 claims 1
239000002872 contrast media Substances 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
239000000594 mannitol Substances 0.000 claims 1
235000010355 mannitol Nutrition 0.000 claims 1
239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
239000000600 sorbitol Substances 0.000 claims 1
235000010356 sorbitol Nutrition 0.000 claims 1
230000000087 stabilizing effect Effects 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 17
239000000843 powder Substances 0.000 abstract description 13
238000011282 treatment Methods 0.000 abstract description 9
239000000126 substance Substances 0.000 abstract description 8
238000003745 diagnosis Methods 0.000 abstract description 5
238000003701 mechanical milling Methods 0.000 abstract 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 36
239000003814 drug Substances 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
229940079593 drug Drugs 0.000 description 20
239000002131 composite material Substances 0.000 description 19
239000000463 material Substances 0.000 description 19
229960004679 doxorubicin Drugs 0.000 description 17
230000027455 binding Effects 0.000 description 13
229910052799 carbon Inorganic materials 0.000 description 13
238000000227 grinding Methods 0.000 description 13
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
238000001179 sorption measurement Methods 0.000 description 12
239000011246 composite particle Substances 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
239000011859 microparticle Substances 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
239000007788 liquid Substances 0.000 description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000000047 product Substances 0.000 description 8
229910045601 alloy Inorganic materials 0.000 description 7
239000000956 alloy Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002372 labelling Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
230000001954 sterilising effect Effects 0.000 description 5
238000004659 sterilization and disinfection Methods 0.000 description 5
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
229940088623 biologically active substance Drugs 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000003795 desorption Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 4
229940055742 indium-111 Drugs 0.000 description 4
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000000149 argon plasma sintering Methods 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229910052738 indium Inorganic materials 0.000 description 3
235000013980 iron oxide Nutrition 0.000 description 3
238000003801 milling Methods 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
240000006108 Allium ampeloprasum Species 0.000 description 2
235000005254 Allium ampeloprasum Nutrition 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical class [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229960003437 aminoglutethimide Drugs 0.000 description 2
229960001220 amsacrine Drugs 0.000 description 2
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000000969 carrier Substances 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000000032 diagnostic agent Substances 0.000 description 2
229940039227 diagnostic agent Drugs 0.000 description 2
238000002059 diagnostic imaging Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000010102 embolization Effects 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229960003540 oxyquinoline Drugs 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
230000005298 paramagnetic effect Effects 0.000 description 2
238000003921 particle size analysis Methods 0.000 description 2
229960002340 pentostatin Drugs 0.000 description 2
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
-1 polyethylenes Polymers 0.000 description 2
238000004663 powder metallurgy Methods 0.000 description 2
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000010926 purge Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000004626 scanning electron microscopy Methods 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000012546 transfer Methods 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
LPZSRGRDVVGMMX-JWXFUTCRSA-N (2s,3s,4s,5s)-2-(fluoromethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](CF)[C@@H](O)[C@H](O)[C@H]1N1C([N+]([O-])=O)=NC=C1 LPZSRGRDVVGMMX-JWXFUTCRSA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
ALHXTYGCVYTWIY-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione Chemical compound N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 ALHXTYGCVYTWIY-UHFFFAOYSA-N 0.000 description 1
ZPZDIFSPRVHGIF-UHFFFAOYSA-N 3-aminopropylsilicon Chemical compound NCCC[Si] ZPZDIFSPRVHGIF-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
PAVHERCAUPDRGZ-UHFFFAOYSA-N OC(O)CC[SiH3] Chemical compound OC(O)CC[SiH3] PAVHERCAUPDRGZ-UHFFFAOYSA-N 0.000 description 1
244000146510 Pereskia bleo Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
238000003723 Smelting Methods 0.000 description 1
241000519995 Stachys sylvatica Species 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
229910052771 Terbium Inorganic materials 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229910001037 White iron Inorganic materials 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
229940098174 alkeran Drugs 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
239000003972 antineoplastic antibiotic Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229910052586 apatite Inorganic materials 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940108502 bicnu Drugs 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000002374 bone meal Substances 0.000 description 1
229940036811 bone meal Drugs 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000002368 cardiac glycoside Substances 0.000 description 1
229940097217 cardiac glycoside Drugs 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229910001567 cementite Inorganic materials 0.000 description 1
238000003508 chemical denaturation Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940035811 conjugated estrogen Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001983 electron spin resonance imaging Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940000733 emcyt Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000005294 ferromagnetic effect Effects 0.000 description 1
239000003302 ferromagnetic material Substances 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
229960001751 fluoxymesterone Drugs 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
230000004907 flux Effects 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940083461 halotestin Drugs 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
239000011019 hematite Substances 0.000 description 1
229910052595 hematite Inorganic materials 0.000 description 1
239000003652 hormone inhibitor Substances 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
KVLGLJRODSYRON-UHFFFAOYSA-N hydroxyurea;urea Chemical class NC(N)=O.NC(=O)NO KVLGLJRODSYRON-UHFFFAOYSA-N 0.000 description 1
229940090411 ifex Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
150000002471 indium Chemical class 0.000 description 1
RJMMFJHMVBOLGY-UHFFFAOYSA-N indium(3+) Chemical compound [In+3] RJMMFJHMVBOLGY-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
238000009413 insulation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000003010 ionic group Chemical group 0.000 description 1
LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
KSOKAHYVTMZFBJ-UHFFFAOYSA-N iron;methane Chemical compound C.[Fe].[Fe].[Fe] KSOKAHYVTMZFBJ-UHFFFAOYSA-N 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940087857 lupron Drugs 0.000 description 1
239000000696 magnetic material Substances 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229940087732 matulane Drugs 0.000 description 1
239000000320 mechanical mixture Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
239000008155 medical solution Substances 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000010309 melting process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910001092 metal group alloy Inorganic materials 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
QMQXDJATSGGYDR-UHFFFAOYSA-N methylidyneiron Chemical compound [C].[Fe] QMQXDJATSGGYDR-UHFFFAOYSA-N 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940087004 mustargen Drugs 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
239000000842 neuromuscular blocking agent Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229910052755 nonmetal Inorganic materials 0.000 description 1
150000002843 nonmetals Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical compound CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229940063238 premarin Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229940063222 provera Drugs 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
229940117820 purinethol Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
238000002791 soaking Methods 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
229930002534 steroid glycoside Natural products 0.000 description 1
150000008143 steroidal glycosides Chemical class 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZEGFMFQPWDMMEP-UHFFFAOYSA-N strontium;sulfide Chemical compound [S-2].[Sr+2] ZEGFMFQPWDMMEP-UHFFFAOYSA-N 0.000 description 1
125000004962 sulfoxyl group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000005211 surface analysis Methods 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
AEGSYIKLTCZUEZ-FZTWWWDYSA-K tri(quinolin-8-yloxy)indigane Chemical compound [111In+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 AEGSYIKLTCZUEZ-FZTWWWDYSA-K 0.000 description 1
239000000814 tuberculostatic agent Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1
229940053890 zanosar Drugs 0.000 description 1
239000010457 zeolite Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Ceramic Engineering (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Apparatus For Disinfection Or Sterilisation (AREA)
Materials For Medical Uses (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Paints Or Removers (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

CZ20021357A 1999-10-18 2000-10-13 Prostředek schopný reagovat na magnetické pole CZ293919B6 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16029399P	1999-10-18	1999-10-18

Publications (2)

Publication Number	Publication Date
CZ20021357A3 CZ20021357A3 (cs)	2002-11-13
CZ293919B6 true CZ293919B6 (cs)	2004-08-18

Family

ID=22576298

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20021357A CZ293919B6 (cs)	1999-10-18	2000-10-13	Prostředek schopný reagovat na magnetické pole

Country Status (15)

Country	Link
EP (1)	EP1221974A2 (es)
JP (3)	JP2003512336A (es)
KR (1)	KR20020064299A (es)
CN (1)	CN1287859C (es)
AU (1)	AU772755B2 (es)
BR (1)	BR0014877A (es)
CA (1)	CA2387925A1 (es)
CZ (1)	CZ293919B6 (es)
DE (1)	DE1221974T1 (es)
ES (1)	ES2182731T1 (es)
HK (1)	HK1045110A1 (es)
IL (1)	IL149004A0 (es)
MX (1)	MXPA02003891A (es)
NZ (1)	NZ518311A (es)
WO (1)	WO2001028587A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9808052D0 (en)	1998-04-17	1998-06-17	Secr Defence	Implants for administering substances and methods of producing implants
AU2004272081A1 (en) *	2003-09-12	2005-03-24	Bankruptcy Estate Of Ferx, Inc.	Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
JP2007001865A (ja) *	2003-09-16	2007-01-11	Ltt Bio-Pharma Co Ltd	脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
EP1719527B1 (en) *	2004-02-09	2016-05-04	Kabushiki Kaisha Sangi	Antitumor agents
PL1735013T3 (pl)	2004-02-20	2012-07-31	Algeta Asa	Cząstki hydroksyapatytu alfa- i beta-emitujące
GB0403856D0 (en) *	2004-02-20	2004-03-24	Algeta As	Composition
JP2006199810A (ja) *	2005-01-20	2006-08-03	Yokohama National Univ	複合粒子およびその製造方法
WO2006109635A1 (ja)	2005-04-06	2006-10-19	Kabushiki Kaisha Sangi	腸管吸収用抗腫瘍剤
CN103494765A (zh)	2009-05-04	2014-01-08	普西维达公司	多孔硅药物洗脱颗粒
CN103282020B (zh) *	2010-11-01	2016-10-26	普西维达公司	用于递送治疗剂的可生物侵蚀的硅基装置
CN104583397B (zh) *	2012-08-28	2018-05-25	生物立方体系统有限公司	用于从生物样品迅速分离核酸扩增反应用生物分子的多孔性固体相及其用途
CA2904077A1 (en)	2013-03-15	2014-09-25	Psivida Us, Inc.	Bioerodible silicon-based compositions for delivery of therapeutic agents
JP6443907B2 (ja) *	2014-02-17	2018-12-26	浩文山本	造影剤の腫瘍への集積を促進するための集積促進剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4243652A (en) *	1978-07-14	1981-01-06	The Procter & Gamble Company	Gastrointestinal scanning agent
EP0343934B1 (en) *	1988-05-24	1995-01-25	Anagen (U.K.) Limited	Magnetically attractable particles and method of preparation
JP3436760B2 (ja) *	1994-07-27	2003-08-18	ハーバートピルグリム	超常磁性粒子
WO1997001304A1 (en) *	1995-06-29	1997-01-16	Mallinckrodt Medical, Inc.	Radiolabeled apatite particles containing a paramagnetic ion
JP3735990B2 (ja) *	1997-01-28	2006-01-18	東ソー株式会社	磁性シリカゲルの製造方法

2000
- 2000-10-13 BR BR0014877-6A patent/BR0014877A/pt not_active IP Right Cessation
- 2000-10-13 AU AU10905/01A patent/AU772755B2/en not_active Ceased
- 2000-10-13 NZ NZ518311A patent/NZ518311A/en unknown
- 2000-10-13 CA CA002387925A patent/CA2387925A1/en not_active Abandoned
- 2000-10-13 IL IL14900400A patent/IL149004A0/xx unknown
- 2000-10-13 KR KR1020027004933A patent/KR20020064299A/ko not_active Ceased
- 2000-10-13 ES ES00972209T patent/ES2182731T1/es active Pending
- 2000-10-13 WO PCT/US2000/028615 patent/WO2001028587A2/en not_active Ceased
- 2000-10-13 JP JP2001531415A patent/JP2003512336A/ja active Pending
- 2000-10-13 DE DE1221974T patent/DE1221974T1/de active Pending
- 2000-10-13 HK HK02106551.6A patent/HK1045110A1/zh unknown
- 2000-10-13 EP EP00972209A patent/EP1221974A2/en not_active Withdrawn
- 2000-10-13 CZ CZ20021357A patent/CZ293919B6/cs not_active IP Right Cessation
- 2000-10-13 CN CNB008173796A patent/CN1287859C/zh not_active Expired - Fee Related
- 2000-10-13 MX MXPA02003891A patent/MXPA02003891A/es not_active Application Discontinuation
2003
- 2003-03-10 JP JP2003063821A patent/JP2003321348A/ja not_active Withdrawn
2005
- 2005-03-28 JP JP2005093293A patent/JP2005200426A/ja active Pending

Also Published As

Publication number	Publication date
NZ518311A (en)	2003-10-31
WO2001028587A2 (en)	2001-04-26
AU772755B2 (en)	2004-05-06
AU1090501A (en)	2001-04-30
KR20020064299A (ko)	2002-08-07
HK1045110A1 (zh)	2002-11-15
EP1221974A2 (en)	2002-07-17
JP2005200426A (ja)	2005-07-28
DE1221974T1 (de)	2003-02-06
MXPA02003891A (es)	2002-12-09
WO2001028587A3 (en)	2002-01-03
IL149004A0 (en)	2002-11-10
CA2387925A1 (en)	2001-04-26
CZ20021357A3 (cs)	2002-11-13
CN1420787A (zh)	2003-05-28
JP2003512336A (ja)	2003-04-02
JP2003321348A (ja)	2003-11-11
ES2182731T1 (es)	2003-03-16
CN1287859C (zh)	2006-12-06
BR0014877A (pt)	2002-06-11

Publication	Publication Date	Title
US6482436B1 (en)	2002-11-19	Magnetically responsive composition
AU744205B2 (en)	2002-02-21	Magnetically responsive composition
JP5079510B2 (ja)	2012-11-21	放射性同位体を結合し得、任意選択的に金属微粒子を含むミクロスフェア、およびそれらの使用方法
US20200276230A1 (en)	2020-09-03	Particles for the treatment of cancer in combination with radiotherapy
CZ293919B6 (cs)	2004-08-18	Prostředek schopný reagovat na magnetické pole
US20060204442A1 (en)	2006-09-14	Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
JP5526156B2 (ja)	2014-06-18	磁性粒子、及びその製造方法、並びに磁性粒子含有製剤
US20030120355A1 (en)	2003-06-26	Biocompatible and biodegradable polymers for diagnostic and therapeutic radioisotope delivery
CN102065905A (zh)	2011-05-18	用于放射性标记合成聚合物的方法
Johnson et al.	2002	The MTC technology: a platform technology for the site-specific delivery of pharmaceutical agents
WO2004034876A2 (en)	2004-04-29	Magnetically guided particles for radiative therapies
Zhao et al.	2012	Thermochemotherapy mediated by novel solar-planet structured magnetic nanocomposites for glioma treatment
Chang et al.	2005	Conjugation of monodisperse chitosan-bound magnetic nanocarrier with epirubicin for targeted cancer therapy
US20070274907A1 (en)	2007-11-29	Magnetically Targetable Mitomycin C Compositions and Methods of Their Use
Guo et al.	2010	Efficient conjugation doxorubicin to bacterial magnetic nanoparticles via a triplex hands coupling reagent
WO2003059325A1 (en)	2003-07-24	Magnetic delivery compositions
WO2000035487A1 (en)	2000-06-22	Pharmaceutical conjugates comprising two active agents

Legal Events

Date	Code	Title	Description
2008-05-14	MM4A	Patent lapsed due to non-payment of fee	Effective date: 20071013